Lumibird S.A (LBIRD) | Financial Analysis & Statements
Lumibird S.A. | Mid-cap | Healthcare
Lumibird S.A. | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
210.1M
Gross Profit
130.8M
62.27%
Operating Income
14.9M
7.10%
Net Income
5.7M
2.71%
EPS (Diluted)
€0.26
Balance Sheet Metrics
Total Assets
429.8M
Total Liabilities
231.8M
Shareholders Equity
198.0M
Debt to Equity
1.17
Cash Flow Metrics
Operating Cash Flow
11.7M
Free Cash Flow
11.4M
Revenue & Profitability Trend
Lumibird S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 210.1M | 206.6M | 194.3M | 166.4M | 129.5M |
| Cost of Goods Sold | 79.3M | 78.0M | 73.0M | 59.2M | 50.0M |
| Gross Profit | 130.8M | 128.5M | 121.3M | 107.2M | 79.5M |
| Operating Expenses | 30.5M | 29.9M | 28.1M | 42.1M | 36.4M |
| Operating Income | 14.9M | 18.4M | 16.3M | 19.7M | 10.1M |
| Pre-tax Income | 6.5M | 7.5M | 14.4M | 17.6M | 7.2M |
| Income Tax | 834.0K | 327.0K | 3.1M | 3.7M | 1.6M |
| Net Income | 5.7M | 7.1M | 11.4M | 13.9M | 5.6M |
| EPS (Diluted) | €0.26 | €0.32 | €0.51 | €0.62 | €0.30 |
Income Statement Trend
Lumibird S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 208.7M | 197.3M | 187.1M | 182.9M | 162.3M |
| Non-Current Assets | 221.1M | 208.0M | 184.9M | 164.8M | 143.1M |
| Total Assets | 429.8M | 405.2M | 372.0M | 347.6M | 305.4M |
| Liabilities | |||||
| Current Liabilities | 79.5M | 74.1M | 119.8M | 57.9M | 57.4M |
| Non-Current Liabilities | 152.3M | 137.8M | 58.8M | 108.4M | 84.0M |
| Total Liabilities | 231.8M | 211.9M | 178.6M | 166.3M | 141.3M |
| Equity | |||||
| Total Shareholders Equity | 198.0M | 193.3M | 193.4M | 181.3M | 164.1M |
Balance Sheet Composition
Lumibird S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 5.7M | 7.1M | 11.4M | 13.9M | 5.6M |
| Operating Cash Flow | 11.7M | 9.8M | 16.0M | 17.4M | 6.7M |
| Investing Activities | |||||
| Capital Expenditures | -22.9M | -25.3M | -20.7M | -18.2M | -12.3M |
| Investing Cash Flow | -22.8M | -46.2M | -29.3M | -28.6M | -67.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 9.4M | 28.7M | -3.6M | 20.4M | 50.6M |
| Free Cash Flow | 11.4M | -4.9M | -28.0M | 6.5M | 747.0K |
Cash Flow Trend
Lumibird S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
61.73
Forward P/E
29.18
Price to Book
1.78
Price to Sales
1.68
PEG Ratio
29.18
Profitability Ratios
Profit Margin
2.71%
Operating Margin
12.01%
Return on Equity
2.91%
Return on Assets
2.23%
Financial Health
Current Ratio
2.63
Debt to Equity
81.34
Beta
1.07
Per Share Data
EPS (TTM)
€0.26
Book Value per Share
€9.00
Revenue per Share
€9.54
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| lbird | 353.3M | 61.73 | 1.78 | 2.91% | 2.71% | 81.34 |
| Eurofins Cerep SAS | 103.9M | 14.33 | - | 10.49% | 17.67% | 0.46 |
| Klea Holding | 53.9M | 17.87 | 1.92 | 5.35% | 8.14% | 21.13 |
| Predilife S.A | 13.9M | - | - | -4,653.75% | 97.76% | -1.16 |
| bioMérieux S.A | 14.2B | 32.96 | 3.37 | 10.68% | 10.86% | 11.65 |
| Eurofins Scientific | 10.6B | 28.48 | 2.56 | 7.71% | 5.85% | 67.05 |
Financial data is updated regularly. All figures are in the company's reporting currency.